These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12064314)

  • 21. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
    Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
    Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2005 Apr; 55(4):542-5. PubMed ID: 15722388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
    Autar RS; Ananworanich J; Apateerapong W; Sankote J; Hill A; Hirschel B; Cooper D; Lange J; Phanuphak P; Ruxrungtham K; Burger D
    J Antimicrob Chemother; 2004 Oct; 54(4):785-90. PubMed ID: 15329366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose reduction effective in alleviating symptoms of saquinavir toxicity.
    Stephan C; Carlebach A; Rottmann C; Haberl A; Dauer B; von Hentig N; Kurowski M; Staszewski S
    Int J STD AIDS; 2007 Feb; 18(2):81-4. PubMed ID: 17331276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
    Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pill burden reduced for saquinavir.
    AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747430
    [No Abstract]   [Full Text] [Related]  

  • 28. Twice daily saquinavir.
    AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356812
    [No Abstract]   [Full Text] [Related]  

  • 29. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
    van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
    Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A further option in PI therapy. Approval of a new protease inhibitor in the USA].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868
    [No Abstract]   [Full Text] [Related]  

  • 33. Fortovase approved: new saquinavir formulation.
    James JS
    AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():18-21. PubMed ID: 11373769
    [No Abstract]   [Full Text] [Related]  

  • 35. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
    van der Lugt J; Gorowara M; Avihingsanon A; Burger D; Ananworanich J; Sringam K; Kerr S; Wit F; Lange J; Ruxrungtham K
    AIDS; 2009 Jun; 23(9):1176-9. PubMed ID: 19451794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NDA submitted for new formulation of saquinavir.
    AIDS Patient Care STDS; 1997 Aug; 11(4):288-9. PubMed ID: 11361847
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
    TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB; Gerstoft J; Youle M; Fox Z; Losso M; Benetucci J; Jayaweera DT; Rieger A; Bruun JN; Castagna A; Gazzard B; Walmsley S; Hill A; Lundgren JD;
    Antivir Ther; 2005; 10(6):735-43. PubMed ID: 16218173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Goodbye, Invirase. Hello, Fortovase.
    Vazquez E
    Posit Aware; 1998; 9(1):45-6. PubMed ID: 11365001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.